Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib plus letrozole vs placebo plus letrozole in postmenopausal women with ER-positive/HER2-negative advanced breast cancer
jRCT2080222282Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2013
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Palbociclib plus letrozole with Placebo plus letrozole (2 arms). Primary endpoint: Progression-free survival (PFS). Started Nov 2013; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080222282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222282.